Back to Search Start Over

MFAP2 promotes HSCs activation through FBN1/TGF‐β/Smad3 pathway.

Authors :
Sun, Yonghong
Chen, Xingxing
Chen, Lili
Bao, Baixin
Li, Chunming
Zhou, Yongning
Source :
Journal of Cellular & Molecular Medicine; Nov2023, Vol. 27 Issue 21, p3235-3246, 12p
Publication Year :
2023

Abstract

Liver fibrosis is a chronic inflammatory process characterized by the accumulation of extracellular matrix (ECM), which contributes to cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that the activation of hepatic stellate cells (HSCs) under an inflammatory state leads to the secretion of collagens, which can cause cirrhosis. In this study, we analysed data from the Gene Expression Omnibus (GEO) databases to identify differentially expressed genes (DEGs) between quiescent and fibrotic HSCs. We found that Microfibril Associated Protein 2 (MFAP2) was elevated in carbon tetrachloride (CCl4)‐induced liver fibrosis and Transforming Growth Factor‐Beta 1 (TGF‐β1)‐activated HSCs. Knockdown of MFAP2 inhibited HSC proliferation and partially attenuated TGF‐β‐stimulated fibrogenesis markers. Bioinformatics analysis revealed that Fibrillin‐1 (FBN1) was correlated with MFAP2, and the expression of FBN1 was significantly upregulated after MFAP2 overexpression. Silencing MFAP2 partially attenuated the activation of HSCs by inhibiting HSC proliferation and decreasing collagen deposits. In vitro results showed that the inhibition of MFAP2 alleviated hepatic fibrosis by inhibiting the activation and inducing the apoptosis of active HSCs in a CCl4‐induced mouse model. In conclusion, our results suggest that MFAP2 is a potential target for the clinical treatment of liver fibrosis. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15821838
Volume :
27
Issue :
21
Database :
Complementary Index
Journal :
Journal of Cellular & Molecular Medicine
Publication Type :
Academic Journal
Accession number :
173438332
Full Text :
https://doi.org/10.1111/jcmm.17884